- Home
- NYC vs NRXS Comparison
NYC vs NRXS Comparison
Compare NYC & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | NYC | NRXS |
|---|---|---|
| Founded | 2013 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.4M | 25.8M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | NYC | NRXS |
|---|---|---|
| Price | $8.09 | $3.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 3.7K | ★ 47.6K |
| Earning Date | 11-19-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $51,688,000.00 | $3,362,320.00 |
| Revenue This Year | $8.40 | $31.05 |
| Revenue Next Year | $1.62 | $137.61 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 36.89 |
| 52 Week Low | $7.03 | $1.33 |
| 52 Week High | $16.30 | $6.20 |
Technical Indicators
Market Signals| Indicator | NYC | NRXS |
|---|---|---|
| Relative Strength Index (RSI) | 50.64 | 69.82 |
| Support Level | $7.40 | $2.63 |
| Resistance Level | $8.29 | $2.78 |
| Average True Range (ATR) | 0.59 | 0.20 |
| MACD | 0.12 | 0.05 |
| Stochastic Oscillator | 84.13 | 60.00 |
Price Performance
Historical ComparisonAbout NYC American Strategic Investment Co.
American Strategic Investment Co is an externally managed company that currently owns a portfolio of commercial real estate located within the five boroughs of New York City, majorly Manhattan. The Company's real estate assets consist of office properties and certain real estate assets that accompany office properties, including retail spaces and amenities.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).